Prostamax

Technical data

CAS

473578-47-1

Molecular formula

C20H33N5O9

Molecular weight

487.51 g/mol

Identity and composition

Prostamax is a synthetic tetrapeptide of sequence Lys-Glu-Asp-Pro (KEDP), belonging to the class of ultrashort peptides or Khavinson-type bioregulators, described in the literature of origin with tropism toward prostatic tissue. It is studied as a possible regulator of prostatic function in research models, not as a therapeutic agent.

Its chemical identity is a reference and is confirmed in PubChem (CID 9848296):

• Name / synonyms: Prostamax, KEDP
• Sequence: Lys-Glu-Asp-Pro (KEDP)
• Molecular formula: C20H33N5O9
• Molecular weight: 487.5 g/mol
• CAS: 473578-47-1
• PubChem CID: 9848296

Product for research use.

Mechanism of action

The mechanism of action of Prostamax (KEDP) is not definitively characterized and must be understood in an educational and preliminary framework. It belongs to the family of short peptides with supposed tissue specificity, and the literature of its institute of origin attributes to it prostatic regulation functions that no were confirmed in independent indexed sources during the research; therefore they must be treated as unverified hypotheses.

The only peer-reviewed support located is a computational work (in silico molecular docking) that evaluated KEDP among 26 ultrashort bioactive peptides. That analysis predicts that KEDP could be transported into the cell interior through transporters of the LAT family (reversible binding to LAT2) and behave as a substrate/inhibitor of PEPT1, which constitutes a hypothesis about its cellular uptake pathway (Int J Mol Sci 2023; PMID 36979488).

The most widespread claims about regulation of chromatin structure or activation of repressed genes come from supplier material and from the originating group's literature, and do not have independent confirmation.

Pharmacokinetics

No human pharmacokinetic data were identified for Prostamax (KEDP) in reviewed sources: there is no validated information on half-life, bioavailability, exposure, or clearance. The only related datum is predictive/in silico, which suggests possible cellular uptake via LAT2 (reversible binding) and PEPT1 transporters (PMID 36979488). No validated dosing data exist. Any kinetic characterization should be considered pending study.

Scientific evidence

The available evidence on Prostamax (KEDP) is preclinical and very limited. No registered clinical trials nor any clinical phase were located for this synthetic tetrapeptide. The peer-reviewed support located is limited to a computational cell-transport study that describes it as a "regulator of prostatic function" when justifying its inclusion (Int J Mol Sci 2023; PMID 36979488).

The suggested indication surrounding prostate health appears in supplier material and in literature from the originating group, but it was not possible to corroborate it with independent in vitro or clinical studies; it is advisable to treat it as an unconfirmed hypothesis. It should be noted that there is a possible nominal confusion with "Prostatex", a distinct peptide bioregulator that does not apply as support for KEDP. Overall, the evidence is preliminary and does not permit conclusions about efficacy.

Research applications

Product for research use.

• It may be of interest for: exploratory in vitro and physicochemical characterization studies; research on ultrashort peptides of the Khavinson class; computational modeling work on cellular transport (e.g. LAT/PEPT families); comparisons within the family of tetrapeptides with the Glu-Asp motif.
• Not applicable for: clinical or animal use, clinical, diagnostic, or therapeutic use; supplement formulation; or as a substitute for medical treatment. It has no FDA approval or identified clinical safety evaluation.

Given the preliminary state of the evidence, its use is restricted to laboratory settings with trained personnel.

Research protocols

The consulted literature does not provide validated doses, concentrations or administration protocols in studies for Prostamax (KEDP). No clinical trials or human dosing data were recorded, and the only peer-reviewed work is computational in nature, without an experimental dose scheme.

In view of the above, it is not possible to indicate a supported protocol. The design of any research procedure remains at the discretion of the investigator and their corresponding committee, starting from the absence of published data and under standard laboratory handling practices.

Reconstitution

As a general laboratory guide for lyophilized peptides, reconstitution is usually performed with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol), which facilitates storage after opening.

• Add the diluent, letting it run down the vial wall, without injecting directly onto the powder.
• Do not shake forcefully: swirl gently until fully dissolved to avoid mechanical stress on the peptide.
• Use aseptic technique and calculate the volume according to the working concentration desired.

These indications are of general handling and do not imply dosing or use in living organisms.

Stability and storage

As a standard peptide handling reference:

• Lyophilized (powder): is the most stable form; it is usually stored refrigerated and, for prolonged storage, frozen, protected from light and humidity.
• Reconstituted (in solution): less stable; it should be kept refrigerated and used within a short period, avoiding repeated freeze-thaw cycles.

No specific stability data for Prostamax were found in the reviewed sources, so these are general laboratory practices and not validated values for this compound.

Safety profile

No documented safety or toxicology data for the synthetic tetrapeptide Prostamax (KEDP) were found in peer-reviewed or regulatory sources. It is important to emphasize that the absence of data does not equate to safety: there is no established safety profile, documented contraindications or identified clinical evaluation.

The compound is for research use only, without FDA approval. It must be handled with protective equipment and standard laboratory practices, avoiding any exposure or consumption.

Comparative context

Prostamax (KEDP) belongs to the family of "Khavinson" short peptides, described informally with supposed tissue specificity. It shares the motif Glu-Asp with other members of the class:

• Epitalon (Ala-Glu-Asp-Gly): unlike KEDP, it has at least published in vitro evidence related to telomerase and telomere length.
• Chonluten (Glu-Asp-Gly): another member that shares the structural motif.

Against these, the primary literature specific to KEDP is notably scarcer. It is informally described as a defined-sequence successor to bovine prostate extracts (Prostatilen/Vitaprost), but this relationship was not verified in an independent source. It should also not be confused with "Prostatex", a distinct prostatic peptide bioregulator.

History and development

Prostamax falls within the line of ultra-short peptides or Khavinson-type bioregulators, a group of short-sequence compounds developed around the idea of tissue specificity. In this context, KEDP is informally described as a defined-sequence successor to bovine prostate extracts (Prostatilen/Vitaprost), although this relationship could not be confirmed in an independent source.

Its chemical identity is publicly registered (PubChem CID 9848296; CAS 473578-47-1), but its research trajectory is incipient: no registered clinical trials were found and the peer-reviewed support is limited to a 2023 computational work on cellular transport. A large part of the functional claims comes from literature of the institute of origin and from suppliers, still without independent corroboration.

FAQ

Customer reviews

Average rating: 5.0 out of 5, based on 3 customer ratings.

Scientific references (4)

Peer-reviewed literature on Prostamax, with its PubMed identifier when available:

• The Influence of the Peptide Bioregulator Prostamax on Heterochromatin of Human Lymphocytes in Situ (Meskhi, et al. · Biofizika · 2004) PMID 15612551.
• Microcalorimetric Study of Human Blood Lymphocytes Culture at Presence of Copper, Cadmium and Prostamax (Kiladze, et al. · Georgian Medical News · 2009) PMID 19359734.
• [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)]. (Dzhokhadze TA, et al. · Georgian Med News · 2012) PMID 23221144.
• [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats]. (Zakutskiĭ AN, et al. · Adv Gerontol · 2006) PMID 17152728.

Other related research peptides

• Testagen
• Thymalin
• Vesugen
• Vilon
• Bronchogen
• Cardiogen
• Cartalax
• Chonluten
• Cortagen
• Crystagen